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Exosomes, a type of extracellular vesicle, have been shown to be involved in many
disorders, including Alzheimer’s disease (AD). Exosomes may contribute to the spread
of misfolded proteins such as amyloid-β (Aβ) and α-synuclein. However, the specific
diffusion process of exosomes and their final destination in brain are still unclear. In
the present study, we isolated exosomes from peripheral plasma and injected them
into the hippocampus of an AD mouse model, and investigated exosome diffusion. We
found that injected exosomes can spread from the dentate gyrus (DG) to other regions
of hippocampus and to the cortex. Exosomes targeted microglia preferentially; this
phenomenon is stable and is not affected by age. In AD mice, microglia take up lower
levels of exosomes. More interestingly, plasma exosomes cluster around the Aβ plaques
and are engulfed by activated microglia nearby. Our data indicate that exosomes can
diffuse throughout the brain and may play a role in the dynamics of amyloid deposition
in AD through microglia.
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INTRODUCTION
Exosomes are a bioactive vesicle (40–100 nm) secreted by various cells in vitro and in vivo
under physiological and pathological conditions. They have been isolated from biological
fluids such as blood, cerebrospinal fluid and urine (Pisitkun et al., 2004; Caby et al.,
2005; Vella et al., 2008). A number of proteins related to neurodegenerative disorders,
including prion disease, Parkinson’s disease and Alzheimer’s disease (AD), have been shown
to be released by cells in association with exosomes (Coleman and Hill, 2015). Evidence
demonstrates that exosomes can facilitate the unique transmissible nature of prions (Fevrier
et al., 2004; Vella et al., 2007; Guo et al., 2016); the exosomes from human-derived
prions infected cells are efficient initiators of prion propagation in uninfected recipient
cells and produce clinical prion disease when inoculated into mice (Vella et al., 2007;
Guo et al., 2016). While prion disease has traditionally been thought to be the only
neurodegenerative disease that is transmissible, misfolded forms of key proteins involved
in other neurodegenerative disorders such as AD, Parkinson’s disease and amyotrophic
lateral sclerosis, may also spread in a similar way (Bellingham et al., 2012; Coleman and Hill, 2015).
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AD, the most common type of dementia, is pathologically
characterized by extracellular deposition of senile plaques and
intracellular accumulation of neurofibrillary tangles (Kandimalla
et al., 2016a,b; Manczak et al., 2016). A growing number
of studies suggest that AD, including amyloid deposits and
neurofibrillary tangles, develops in a prion-like manner (Eisele
et al., 2009; Frost and Diamond, 2010; Coleman and Hill,
2015). Experimental seeding of amyloid-β (Aβ) pathology has
been shown in primates and transgenic mice by intracerebral
or peripheral inoculation with AD brain homogenate (Baker
et al., 1994; Meyer-Luehmann et al., 2006; Eisele et al.,
2010; Hamaguchi et al., 2012; Heilbronner et al., 2013).
An autopsy study also found marked deposition of gray
matter and vascular Aβ in relatively young patients with
iatrogenic Creutzfeldt–Jakob disease (Jaunmuktane et al., 2015).
Therefore, exosomes have been suspected to participate in
the prion-like propagation of lesions in AD (Bellingham
et al., 2012; Vingtdeux et al., 2012; Coleman and Hill, 2015).
This idea is supported by the observation that exosomes
isolated from either neuronal cell cultures or brain contain
Aβ precursor protein (APP) and APP-processing products,
including C-terminal fragments and Aβ (Vingtdeux et al.,
2007; Perez-Gonzalez et al., 2012). Moreover, exosomes can
cross the blood–brain barrier and are exploited as drug
delivery vehicles in many studies (Alvarez-Erviti et al., 2011;
Haney et al., 2015). Exosomes contribute to the long distance
transmission of biological information and therefore affect
many physiological and pathological processes. However,
the specific diffusion process of exosomes in the brain is
still unclear. In addition, it is unknown if the peripheral
circulation can communicate with the central nervous system via
exosomes.
Microglia, the resident immune cells in the brain, phagocytose
dead cells and help to clear misfolded protein aggregates such as
amyloid plaques in AD (Bard et al., 2003). In vitro studies show
that neuron-derived and oligodendrocyte-derived exosomes are
incorporated into microglia (Fitzner et al., 2011; Yuyama et al.,
2012). It is unknown, however, whether microglia are also the
final destination of peripheral exosomes. Exosomes from brain
can enter the bloodstream and have been explored as potential
biomarkers of preclinical AD or other neurodegenerative
diseases (Shi et al., 2014; Fiandaca et al., 2015; Goetzl et al.,
2015). Exosomes are reported to dramatically stimulate Aβ fibril
formation by its surface glycosphingolipids, and mediate Aβ
fibrils uptake into microglia in a phosphatidylserine-dependent
manner (Yuyama et al., 2012). Intracerebrally injected exosomes
result in reduction of Aβ pathology (Yuyama et al., 2014, 2015).
Secretion of exosomes is decreased in progranulin-associated
frontotemporal dementia (Benussi et al., 2016). However,
Dinkins et al. (2014) show that exosomes interfere with the
uptake of Aβ by primary cultured astrocytes and microglia
in vitro. Preventing exosome secretion with GW4869 can reduce
amyloid plaque formation in vivo. Conversely, increasing the
secretion of exosomes enhances plaque formation (Dinkins
et al., 2014, 2015). Furthermore, reducing exosome secretion
by genetic neutral sphingomyelinase-2 defects in 5XFAD mice
ameliorates AD-associated pathology and improves cognition
(Dinkins et al., 2016). Further studies are needed to explore
the role of exosomes in AD pathology, especially in amyloid
deposition.
In the present study, we traced the spread of exogenous
plasma exosomes to explore the specific diffusion processes of
exosomes in mouse brain and their target cells. In addition, we
investigated the role of exosomes in amyloid deposition in an AD
transgenic mouse model.
MATERIALS AND METHODS
Animals
hAPP-J20 mice expressing human APP with Swedish
and Indiana (KM670/671NL, V717F) mutations were
purchased from the JAX MMRRC (Stock # 034836). They
were housed in groups of five under a normal 12 h light/dark
cycle, kept under standard temperature and humidity and
in pathogen free conditions. All experiments were approved
by the Institutional Animal Care and Use Committee of
Zhejiang University and carried out in accordance with the
National Institutes of Health guidelines for the use of laboratory
animals.
Cell Cultures
The human neuroblastoma cell line SH-SY5Y (SY5Y) expressing
GFP was cultured using Dulbecco’s modified Eagles medium
(DMEM) supplemented with 10% fetal bovine serum in a 5%
CO2 humidified incubator at 37◦C.
Blood Collection and Platelet Free Plasma
(PFP) Preparation
We collected blood from hearts of 2 months old C57BL/6 mice,
then prepared platelet free plasma (PFP) as described previously
(György et al., 2014; Osteikoetxea et al., 2015) and in accordance
with the standardization of International Society on Thrombosis
andHemostasis on blood sampling and handling forMV analysis
(Lacroix et al., 2013). Briefly, in order to prevent release of
platelet-derived EVs in vitro, blood was collected into acid-
citrate-dextrose tubes (Greiner Bio-One; György et al., 2014).
Blood was centrifuged (2× 15min, 3000 g at 4◦C). PFP was
stored at−80◦C until use.
Exosome Isolation
We isolated exosomes from PFP using total exosome isolation
reagents (Life Technologies). Vesicles were enriched according
to the manufacturers’ instructions. Briefly, the plasma sample
was centrifuged (20 min, 2000× g; 20 min, 10,000× g at room
temperature) to remove cells and debris. The supernatant was
transferred to a new tube, then 0.5 volumes of 1× PBSwere added
and mixed, before adding 0.05 volumes of Proteinase K, followed
by 10 min incubation at 37◦C. Then 0.2 volumes of exosome
precipitation reagent was added to the sample following by
incubation at 4◦C for 30 min. After incubation, the sample
was centrifuged at 10,000× g for 30 min at room temperature.
Exosomes were contained in a pellet at the bottom of the tube.
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Electron Microscopy
Exosomes were resuspended in PBS at a concentration of
100 µg protein/ml. The exosome mixture was then applied
to the grid and negatively stained with 2% phosphotungstic
acid. Transmission images were acquired using an HT-7700
transmission electron microscope (Hitachi, Tokyo, Japan).
Nanoparticle Tracking Analysis
To quantify exosomes and characterize their dispersion and
size distribution, nanoparticle tracking analysis (NTA) was
performed using a NanoSight LM10 instrument (Malvern,
Instruments) and NTA Version 2.3 Build 0034 software. For
NTA, 100 µl of exosomes were diluted in 50 ml PBS, and particle
size was calculated automatically for at least 5000 particles. PBS
was assessed before the experiment to ensure that it was particle-
free.
Western Blotting Analysis
Exosome samples were subjected to SDS-PAGE on 12%
gels, followed by Western blotting. Proteins were blotted
to PVDF membranes, and membranes were blocked in 5%
milk in PBS/0.1% Tween 20 (PBS/Tween). The following
primary antibodies were used: rabbit anti-ALIX (1:1000, Abcam,
ab88388), rabbit anti-Tsg101 (1:2000, Abcam, ab125011), rabbit
anti-GM130 (1:1000, ABclonal, A5344). Blots were visualized
using HRP-conjugated secondary antibodies and the ECL
Detection Reagent (Thermo Fisher Scientific) and were imaged
on a LAS3000 image reader (Raytest, Germany).
Exosome Tracking
Exosomes were labeled with a red fluorescent lipophilic
dye DiI (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine
perchlorate; Beyotime, C1036), allowing monitoring of exosome
movement. DiI emits strong fluorescence when excited by
green light and incorporated into membranes, and does not
disrupt the membrane properties. Exosomes were resuspended
in sterile PBS and incubated with 5 µM DiI for 10 min.
DiI-exosomes were then washed and resuspended in sterile
PBS three times to remove free DiI and other impurities
such as lipoproteins. The control was prepared by DiI
incubation with PBS, which was washed as for the DiI-exosome
preparation.
Cell Incubation with DiI-Exosomes
DiI-exosomes were administered to SH-SY5Y cells and incubated
for 24 h in serum-free conditions at a working concentration
of 2 µg protein/ml. Images were acquired using an inverted
microscope (Olympus, IX53).
Stereotaxic Injection of Exosomes into the
Mouse Hippocampus
The DiI-exosome solution (3 µl at 1 µg protein/µl) and the
control (3 µl) was stereotactically injected into the dentate gyrus
(DG) of the mouse hippocampus using a stereotactic apparatus
(KOPF), at the following coordinates (relative to Bregma):
anterior posterior: −2.0, medial lateral: ± 1.6, dorsal ventral:
−2.1. The brains were perfused with cold 0.9% saline and fixed
in 4% paraformaldehyde for 3–20 days after injection.
Immunofluorescence Staining
Mice were perfused transcardially with 0.9% saline. Brains were
removed immediately and immersed in 4% paraformaldehyde.
After dehydration in 30% sucrose, coronal brain sections (20µm)
were prepared with a sliding microtome (Leica). Brain slices were
stained as previously described (Zheng et al., 2015). In brief, brain
slices were blocked with blocking buffer (10% fetal bovine serum,
1% nonfat milk, 0.2% gelatin in PBS containing 0.5% Triton X-
100) and incubated with primary antibodies: rabbit anti-MAP-2
(1:600, #4542, CST), rabbit anti-IBA1 (1:600, 019-19741 Wako),
mouse anti-6E10 (1:1000, SIG-39320, Covance), monoclonal
anti-glial fibrillary acidic protein (GFAP, 1:400, G3893, Sigma).
After incubating with primary antibodies overnight at 4◦C, the
brain sections were washed three times with PBS containing
0.5% Triton X-100 and three times with PBS. Slices were then
incubated with the appropriate secondary antibodies: AlexaFluor
488 AffiniPure donkey anti-rabbit lgG (1:300, 711-545-152,
Jackson ImmunoResearch), AlexaFluor 647 donkey anti-rabbit
(1:1000, A-31571, Invitrogen), AlexaFluor 488 donkey
anti-mouse (1:1000, A-21206, Invitrogen). After incubation
with secondary antibodies for 2 h at room temperature, the
brain sections were washed once with PBS containing 0.5%
Triton X-100 and three times with PBS. Free floating brain
sections were mounted on glass slides with a drop of 4′,6-
diamidino-2-phenylindole (DAPI) Fluoromount-G mounting
medium (0100-20, Southern Biotech). Images were taken using
confocal microscope (OLYMPUS FV1000) and a large field
of view CCD system (Zeiss, Axio Scan.Z1). Then images were
processed using Fluoview Viewer (FV10-ASW; Olympus) and
the ZEN 2 (blue edition, V1.0 en; Zeiss) software packages,
respectively.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
version 6.05 for Windows (GraphPad Software, San Diego, CA,
USA). All values in the figures are presented as mean± standard
error of the mean (SEM). Differences between two means were
assessed with unpaired two-tailed Student’s t test. P values of less
than 0.05 were considered statistically significant.
RESULTS
Characterization of Exosomes
Exosomes were analyzed for morphology and size distribution
using a Nanosight system and transmission electron microscope,
respectively (Figures 1A,B). Consistent with recent reports
(Momen-Heravi et al., 2012; Chernyshev et al., 2015), the
exosomes were observed as a homogenous population with
low dispersity and with a peak in particle size at 137 nm
(Figure 1A). Streaming, a factor related to Brownian motion
of small particles, caused the reported size distribution to
be larger than actual size distribution (Scott et al., 2005).
Transmission electron microscopy revealed that the media
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FIGURE 1 | Characterization of plasma exosomes. (A) Exosomes were measured via nanoparticle tracking analysis (NTA) analysis to quantify exosomes and
show their size distribution. Exosomes comprise a homogenous population with a peak in diameter at 137 nm and low polydispersity. (B) Exosomes (1,00,000× g
pellet) underwent negative staining with phosphotungstic acid and were examined by electron microscopy. Scale bars, 100 nm. (C) Fractions of exosomes were
analyzed by Western blotting to detect the exosomal markers Alix and Tsg101, and the negative marker GM130. All approximate protein masses are represented
in kDa.
contain morphologically distinct particles of approximately
60–110 nm diameter that are membrane bound and ‘‘cup
shaped’’ (Figure 1B) as previously described. The presence of
exosomes was confirmed by detecting the exosomal markers Alix
and Tsg101, and negative marker GM130 in Western blotting
analysis (Figure 1C).
Exosomes Can Diffuse Over Great
Distances in Mouse Brain
Several reports have revealed that exosomes facilitate the
unique transmissible nature of prions (Vella et al., 2007; Guo
et al., 2016). Key proteins involved in other neurodegenerative
disorders such as AD, Parkinson’s disease and amyotrophic
lateral sclerosis may also spread via misfolded proteins similar
to prions (Bellingham et al., 2012; Coleman and Hill, 2015).
To identify the trail of exosomes in the brain, we injected
DiI-labeled exosomes into the mouse DG and traced the
movement of the exosomes over time (3, 6 and 20 days
after injection). We found that exosomes could spread from
the injection site to other areas of hippocampus gradually
and moved to the cortex as time went on (Figures 2A–C).
Fluorescent images showed the most abundant exosomes in
the cortex on day 20, but none were observed on day 3;
a small portion of exosomes began to appear in the cortex
on the 6th day after injection (Figure 2A). On the 20th
day, most of the exosomes had spread from hippocampus to
the cortex and only a few exosomes were retained in the
hippocampus (Figures 2B,C). We prepared 15 coronal brain
sections at approximately 200 µm intervals from mice brains
20 days after injection. Exosomes were observed in most brain
sections (approximately 12–13 brain sections, Supplementary
Figure S1). In the hippocampus, exosomes were concentrated
in the CA3 region of mouse hippocampal slices, very little were
observed in CA1 or CA2 of the hippocampus (Figure 2D).
Meanwhile, the control group showed little red fluorescence in
the hippocampus and cortex at 3, 6 and 20 days after injection
(Figure 2E, Supplementary Figure S2). Yuyama et al. (2014)
continuously injected exosomes intraventricularly for 14 days
and found significant reductions in Aβ levels and Aβ-associated
synaptotoxicity in the mouse hippocampus, as well as reductions
in Aβ deposition.
Exosomes Target Microglia Preferentially
and Stably in Mouse Brains
As the resident immune cells of brain, microglia have
been involved in brain injury and various neurological
disorders. Recent studies show that oligodendrocyte-derived
and N2a-derived exosomes were preferentially internalized
by primary microglia in vitro (Fitzner et al., 2011). When
exosomes were administered into mouse brain, microglia
engulfment of exosomes was observed a few hours later.
To further follow the fate of exosomes over a period of
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FIGURE 2 | Exosomes diffuse over great distances in mouse brain. Images were captured at 3, 6 and 20 days after injection of DiI-stained exosomes into the
hippocampal dentate gyrus (DG) region. DiI-exosomes can emit red fluorescence. (A) Representative photomicrographs showing the distribution of exosomes in
cortex. In order to show the structure more clearly, we marked the forceps major corpus callosum (fmj) in figures. The content of exosomes increased with time in
cortex. (B,C) Representative photomicrographs showing the distribution of exosomes in hippocampus in front of (B) and behind (C) the injection point. Exosomes
show better diffusion in hippocampus on day 6 than on day 3. On the 20th day, most of the exosomes spread from the hippocampus to the cortex. (D) Images were
captured 3 days after injection of exosomes in hippocampal DG region. The figure on the left show DiI-exosomes and counterstain with 4′,6-diamidino-
2-phenylindole (DAPI), while the figure on the right shows DiI-exosomes only. The arrow shows the projection direction from the DG region to CA3. Exosomes
concentrated in hippocampal CA3 region. In contrast, very few exosomes are observed in area CA1 and CA2 of the hippocampus. (E) The control (DiI incubation
with PBS and being re-isolated, washed, resuspended in sterile PBS for three times as the DiI-exosomes’ preparation) were injected into hippocampal DG region.
Representative photomicrographs show images captured at 20 days after injection and the images captured at 3 and 6 days after injection are shown in
Supplementary Figure S2. Scale bars, 50 µm.
time in brain, we detected their presence in target cells on
the 20th day after intracerebral injection. We observed that
exosomes were still predominantly localized in Iba1-positive
microglia in cerebral cortex and hippocampus (Figures 3A,B).
In contrast, very little uptake of exosomes was observed
in GFAP-positive astrocytes (Figure 3C) or MAP-2-positive
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FIGURE 3 | Exosomes target microglia preferentially and stably. Images were captured at 20 days after DiI-exosome injection in non-transgenic mice
(17 months old). (A,B) Microglia in the hippocampus and cortex were stained with anti-Iba1 antibody. Merged figures show that the majority of exosomes are
localized in microglia. Inset, higher magnification of an exosome-containing microglia cell labeled with Iba-1 antibody. (C,D) Exosomes (red) are not taken up by
astrocytes labeled with anti- glial fibrillary acidic protein (GFAP) antibody (green, C) or neurons labeled with anti-MAP2 (green, D) in cortex and hippocampus.
(E) SH-SY5Y cells were incubated with DiI-exosomes in vitro. After 24 h incubation, images were acquired using an inverted microscope. Compared with the control
group (DiI incubation with PBS and being re-isolated, washed as the DiI-exosomes’ preparation and the same volume of control was incubated with sy5y cells),
fluorescent signals are observed in the medium incubated with DiI-exosomes but are rarely detected in SH-SY5Y cells and cannot be detected in the control group.
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neurons (Figure 3D) in cerebral cortex and hippocampus.
Weak fluorescent signals could be occasionally detected in
neurons of the DG, suggesting limited neuronal uptake of
exosomes. Accumulation of exosomes may occur in the
hippocampal CA3 region along the projection from the DG to
the CA3 region (Figure 2D). We next used the neuroblastoma
cell line SH-SY5Y with DiI-exosomes in vitro. After 24 h
incubation with labeled exosomes, fluorescent signals were
observed in the medium but rarely detected inside SH-SY5Y
cells (Figure 3E). Combined with previous experimental results
(Fitzner et al., 2011; Yuyama et al., 2012), our data demonstrated
that exosomes target microglia preferentially and stably in mouse
brains.
Aging Does Not Affect the Phagocytosis of
Exosomes by Microglia
Age-associated microglial senescence in the brain leads
to abnormal function and may eventually promote
neurodegeneration (Luo et al., 2010). Since cellular
internalization of exosomes occurs through phagocytosis in
microglia, we investigated whether aging could affect the ability
of microglia to engulf exosomes. We compared phagocytosis
of exosomes by microglia in the hippocampus between young
(3.7 months old) and old (17 months old) mice. No significant
difference was observed (Figures 4A–C, Supplementary
Figure S3).
The Ability of Microglial Engulfment of
Exosome in AD Transgenic Mouse Brain Is
Reduced
Several studies revealed that microglial phagocytic capacity is
impaired in AD (Hickman et al., 2008). In this study, we
compared microglial phagocytosis of exosomes in hippocampus
between 17 month-old hAPP-J20 mice and littermate controls.
We observed that microglial phagocytosis of exosomes was lower
in hAPP-J20 mice (Figures 4D–F, Supplementary Figure S4).
Exosomes Cluster Around the Aβ Plaques
and Are Engulfed by Activated Microglia
Nearby
One pathological feature of AD is extracellular amyloid
deposition and the presence of senile plaques (Beyreuther
and Masters, 1991). Continuous intracerebral injection
of neuroblastoma-derived or neuronal exosomes into AD
transgenic mice results in marked reduction in Aβ pathology
(Yuyama et al., 2014, 2015). However, injection of the astrocyte-
derived exosomes into the brains of 10-day-old 5XFAD mice
stimulates aggregation of Aβ in vivo (Dinkins et al., 2014).
Here, we injected plasma exosomes into 17-month old AD
mice to assess the relationship between plasma exosomes and
Aβ plaques. We observed that exosomes clustered around the
Aβ plaques, especially the large plaques (Figure 5). It has been
demonstrated that extracellular Aβ plaques are often surrounded
by activated microglia in both humans with AD (Styren et al.,
1990) and AD animal models (Frautschy et al., 1998). We
confirmed this phenomenon in hAPP-J20 mice (Figure 5). It
is interesting that most exosomes clustered around Aβ plaques
were localized in activated microglia (Figure 5), suggesting that
microglia may play a role in AD pathogenesis through engulfing
exosomes.
DISCUSSION
Neurodegenerative diseases, including AD, begin with
dysfunction in a discrete region, and involve much larger
areas of the brain at later stages. AD pathology has been
proposed to spread through functionally and anatomically
connected brain regions (Braak and Braak, 1991; Buckner
et al., 2005; Braak et al., 2006; Harris et al., 2010), perhaps by a
prion-like mechanism (Eisele et al., 2009; Frost and Diamond,
2010; Acquatella-Tran Van Ba et al., 2013; Marciniuk et al.,
2013). Previous studies have demonstrated that exosomes
facilitate the unique transmissible nature of prions (Vella et al.,
2007; Guo et al., 2016). Many proteins associated with AD
including APP and the APP-processing products, C-terminal
fragments and Aβ can be found in exosomes from both neuronal
cell cultures and brain tissues (Rajendran et al., 2006; Vingtdeux
et al., 2007; Perez-Gonzalez et al., 2012). Pathogenic proteins
involved in other neurodegenerative disorders also have been
shown to be released by cells in association with exosomes
(Bellingham et al., 2012).
In our study, we observed that exosomes diffused from
the injection site in the DG to other brain regions, which
could indicate the potential for exosome-bound pathogenic
proteins to travel great distances in the brain. Previous studies
have also shown that exosomes can cross the blood-brain
barrier. When combined with our result that plasma exosomes
can spread in the brain parenchyma, these data suggest that
exosomes from peripheral blood may communicate with the
CNS in physiological and pathological conditions. In addition,
we found that exosomes concentrated in the CA3 region of the
hippocampus. In contrast, very few exosomes were observed
in the CA1 and CA2 areas of the hippocampus. This may
due to projections from the DG to CA3 region. Synaptic
connections between the mossy fibers of the granule cells in
the DG and CA3 neurons, and the Schaffer collaterals from
CA3 to CA1 neurons constitute the forward hippocampal
polysynaptic circuit in mice (Harris et al., 2010). Further
studies are needed to explore the relationship between exosomal
diffusion and axonal projections in the hippocampus. It is
reported that approximately 98% of all potent drugs that may
be therapeutic for many neurological diseases in the CNS
failed in clinic trials because of their inability to cross the
blood-brain barrier (Pardridge, 2012). Exosomes have been
increasingly used as delivery platforms, encapsulating reagents
or siRNAs (Alvarez-Erviti et al., 2011; Haney et al., 2015).
Therefore, the exosomal diffusion in brain observed in our
study further supports the feasibility of using exosomes as
a delivery system from the peripheral circulation to the
brain.
Our data are consistent with previous observations
that oligodendrocyte-derived exosomes are specifically and
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FIGURE 4 | Aging does not affect the phagocytosis of exosomes by microglia DiI-exosomes were stereotactically injected into the hippocampus.
Hippocampal immunofluorescence staining was detected after 20 days. (A,B) Hippocampal sections from 3.7 (A) and 17 (B) month old mice were stained with
anti-Iba1 antibody (green). (C) Quantification of the relative uptake of exosomes by microglia (mean gray value of exosomes co-localized with microglia/total
exosomes) in hippocampus of 3.7 and 17 months old mice (double-blinded, ImageJ analysis). ns, no statistically difference. EXO, exosomes. (D,E) Exosomes target
microglia in hAPP-J20 mice with lower efficiency. Hippocampal sections from hAPP-J20 transgenic mice (D) and non-transgenic mice (E) were stained with anti-Iba1
antibody. (F) Quantification of the relative uptake of exosomes by microglia in hippocampus of hAPP-J20 transgenic mice and non-transgenic mice. N = 3 (5 brain
slices for each mouse); ∗∗P < 0.01, two-tailed student’s t test was used.
efficiently taken up by microglia (Fitzner et al., 2011). Harris
et al. (2010) reported that oligodendrocyte-derived exosomes
are selectively taken up by microglia via micropinocytosis;
Yuyama et al. (2012) further showed that microglia engulf
exosomes in a phosphatidylserine-dependent manner. In
agreement with these previous studies, we found that plasma
exosomes were efficiently taken up by microglia. Unlike
short-term tracking in a previous report, we investigated the
diffusion of exosomes in the brain for up to 20 days. Our
results showed that exosomes can spread stably in the brain
and are largely taken up by microglia. A portion of exosomes
not engulfed by microglia were observed in the cortex and
hippocampus, which rules out the possibility that the spreading
of exosomes is due to the migration of microglia containing
labeled exosomes. To evaluate whether neurons and astrocytes
also engulf exosomes, we tested fluorescently-labeled exosomes
in these cells. In contrast to microglia, very little uptake of
exosomes was observed in astrocytes or neurons in cerebral
cortex or hippocampus, which is supported by in vitro results
(Fitzner et al., 2011).
The proteins and nucleic acids carried by exosomes play
important roles in signal delivery and material exchange
between cells. In a similar fashion, microglia may communicate
with the other cells in brain through exosomes. However,
exosomes can potentially carry pathogenic proteins, such as
prions, propagating their toxic assemblies and promoting
the progress of diseases (Vella et al., 2007; Guo et al.,
2016). Engulfment of exosomes by microglia may prevent
the propagation of exosome-bound pathogenic proteins to
other cells. Interestingly, insulin-degrading enzyme and Aβ-
degrading enzymes have been found in the exosomes secreted
by microglia (Tamboli et al., 2010). Therefore, exosomes
may enhance the ability of microglia to clear pathogenic
proteins. Further studies are required to clarify the roles of
exosomes in the CNS and their specific relationships with
microglia.
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FIGURE 5 | Exosomes cluster around the Aβ plaques and are engulfed by nearby activated microglia. (A) Representative photomicrographs showing the
distribution of DiI-exosomes in hippocampus of hAPP-J20 transgenic mice. Microglia are labeled with anti-Iba1 (blue), exosomes are labeled with DiI (red) and
anti-6E10 is used to label Aβ plaques (green). (B) Higher magnification images of the boxed areas in (A) show a single Aβ plaque. Exogenously injected exosomes
and microglia cluster around the Aβ plaque. Moreover, the exosomes are largely localized in this microglia. (C) Representative confocal image through a single plane
of exosome (red) internalized by microglia (green) in the hippocampus.
Aging effects on microglial phagocytosis has been widely
studied. A recent report suggests that the ability of primary
murine microglia to take up exosome-associated oligomeric
α-synuclein is compromised in aged mice (Bliederhaeuser et al.,
2016). Moreover, phagocytic deficits are found in human
monocytes from elderly individuals (Bliederhaeuser et al., 2016).
Our studies in mouse brain show that aging did not alter the
ability of microglia to take up plasma exosomes, suggesting that
dysregulation of microglia caused by aging may not influence the
engulfment of plasma exosomes.
Impaired microglial phagocytic capacity has also been
observed in neurodegenerative diseases such as AD. Here
we show that exosomes targeted microglia in hAPP-J20
mice with lower efficiency compared with control littermates.
Microglia pro-inflammatory activation and dysfunction has
been observed in AD brains. However, both the decreased
amyloid-clearing ability of microglia (Flanary, 2005) and the
damage to microglia by amyloid (Korotzer et al., 1993) have
been reported in AD brain. von Bernhardi (2007) proposed
that AD is caused by dysfunctional microglia rather than
by hyperactive microglia. Microglia from aged PS1-APP mice
have a 2–5 fold decrease in the expression of the Aβ-
binding scavenger receptors RAGE, scavenger receptor A and
CD36 compared to their littermate controls (Hickman et al.,
2008), which indicates microglial dysfunction in AD and
supports the idea that microglia senescence contributes to
the pathogenesis of AD. Therefore, the observation in our
study that engulfment of exosomes is reduced in the AD
mouse model may due to phagocytic deficits of microglia
in AD.
Recently, in vitro studies demonstrate that a fraction of Aβ
peptide is released in association with exosomes (Rajendran et al.,
2006). Exosomes enhance conformational changes in Aβ to form
nontoxic amyloid fibrils and promote the uptake and clearance
of Aβ by microglia (Yuyama et al., 2012). These findings suggest
that exosomes are involved in Aβ metabolism in the brain.
Here, we observed that exogenously injected exosomes clustered
around Aβ plaques, especially large plaques, in hAPP-J20 mice.
Interestingly, exosomal markers are found to be enriched in
amyloid plaques in the brains of Tg2576 mice (Kokubo et al.,
2005) and postmortem human AD patients (Rajendran et al.,
2006). Meanwhile, activated microglia were found to surround
the extracellular Aβ plaque as previously reported (Rogers et al.,
1988; Frautschy et al., 1998; Stalder et al., 1999; Buckner et al.,
2005). The confocal images show that most of the exosomes
around the plaques are localized in these activated microglia.
Yuyama et al. (2014, 2015) reported that glycosphingolipids
are abundant in exosomes and Aβ can bind to the exosome
surface via the glycan moieties of glycosphingolipids. Exosome-
bound Aβ is then transported into microglia for degradation,
resulting in a decrease in Aβ levels, Aβ plaques and Aβ-related
pathologies in APP mice. Combined with the observations in
our study, these data suggest that exosomes may play a role in
trafficking of Aβ aggregates through microglia during disease
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progression. However, injection of astrocyte-derived exosomes
into the brains of 10-day old 5XFADmice stimulated aggregation
of Aβ in at the site of injection (Dinkins et al., 2014). Increasing
serum exosome content by treating 5XFAD mice with ceramide
ultimately enhanced plaque formation (Dinkins et al., 2015) The
size of amyloid plaques changes over days in brains of AD
modelmice (Bolmont et al., 2008).Whether the plasma exosomes
support this change needs further exploration. It is worth
noting that although engulfment of exosomes by microglia is
inefficient in AD transgenic mice overall, the activated microglia
clustering around plaques can take up exosomes effectively. This
may indicate that phagocytosis in microglia clustering around
plaques is stronger than other parts of the brain. Whether
the plasma exosomes can decrease Aβ plaques and play a
role in pathological process of AD, as well as which type
of cells these functional exosomes come from, needs further
investigation.
Overall, our study described the movement of exosomes
across great distances in the brain, which can help to advance
medical research of exosomes in neurodegenerative diseases.
Moreover, exosomes may play roles in amyloid deposition
through microglia in AD.
AUTHOR CONTRIBUTIONS
BZ, BS and TZ conceived and designed the study;
TZ, JP, YC, YM, ZG, HP, LZ and HZ performed the
experiments; JP and TZ processed and analyzed all data;
BS and BZ wrote the manuscript with input from TZ. All
authors have read and approved the final version of the
manuscript.
ACKNOWLEDGMENTS
This work was supported by grants from the National 973
Project (2013CB530900, 2013CB530904), the National Nature
Science Foundation of China [grant numbers 81400866,
81400933] and Nature Science Foundation of Zhejiang
Province(LY17H090005).
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/ 10.3389/fnagi.
2017.00012/full#supplementary-material
REFERENCES
Acquatella-Tran Van Ba, I., Imberdis, T., and Perrier, V. (2013). From prion
diseases to prion-like propagation mechanisms of neurodegenerative diseases.
Int. J. Cell Biol. 2013:975832. doi: 10.1155/2013/975832
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., and Wood, M. J.
(2011). Delivery of siRNA to the mouse brain by systemic injection of targeted
exosomes. Nat. Biotechnol. 29, 341–345. doi: 10.1038/nbt.1807
Baker, H. F., Ridley, R. M., Duchen, L. W., Crow, T. J., and Bruton, C. J.
(1994). Induction of β (A4)-amyloid in primates by injection of Alzheimer’s
disease brain homogenate. Comparison with transmission of spongiform
encephalopathy.Mol. Neurobiol. 8, 25–39. doi: 10.1007/bf02778005
Bard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., et al.
(2003). Epitope and isotype specificities of antibodies to β-amyloid peptide for
protection against Alzheimer’s disease-like neuropathology. Proc. Natl. Acad.
Sci. U S A 100, 2023–2028. doi: 10.1073/pnas.0436286100
Bellingham, S. A., Guo, B. B., Coleman, B. M., and Hill, A. F. (2012). Exosomes:
vehicles for the transfer of toxic proteins associated with neurodegenerative
diseases? Front. Physiol. 3:124. doi: 10.3389/fphys.2012.00124
Benussi, L., Ciani, M., Tonoli, E., Morbin, M., Palamara, L., Albani, D.,
et al. (2016). Loss of exosomes in progranulin-associated frontotemporal
dementia. Neurobiol. Aging 40, 41–49. doi: 10.1016/j.neurobiolaging. 2016.
01.001
von Bernhardi, R. (2007). Glial cell dysregulation: a new perspective on Alzheimer
disease. Neurotox. Res. 12, 215–232. doi: 10.1007/bf03033906
Beyreuther, K., and Masters, C. L. (1991). Amyloid precursor protein (APP)
and β A4 amyloid in the etiology of Alzheimer’s disease: precursor-product
relationships in the derangement of neuronal function. Brain Pathol. 1,
241–251. doi: 10.1111/j.1750-3639.1991.tb00667.x
Bliederhaeuser, C., Grozdanov, V., Speidel, A., Zondler, L., Ruf, W. P.,
Bayer, H., et al. (2016). Age-dependent defects of alpha-synuclein oligomer
uptake in microglia and monocytes. Acta Neuropathol. 131, 379–391.
doi: 10.1007/s00401-015-1504-2
Bolmont, T., Haiss, F., Eicke, D., Radde, R., Mathis, C. A., Klunk, W. E., et al.
(2008). Dynamics of the microglial/amyloid interaction indicate a role in
plaque maintenance. J. Neurosci. 28, 4283–4292. doi: 10.1523/JNEUROSCI.
4814-07.2008
Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related
changes. Acta Neuropathol. 82, 239–259. doi: 10.1007/bf00308809
Braak, H., Rüb, U., Schultz, C., and Del Tredici, K. (2006). Vulnerability of cortical
neurons to Alzheimer’s and Parkinson’s diseases. J. Alzheimers Dis. 9, (3 Suppl),
35–44.
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F.,
et al. (2005). Molecular, structural, and functional characterization of
Alzheimer’s disease: evidence for a relationship between default activity,
amyloid and memory. J. Neurosci. 25, 7709–7717. doi: 10.1523/JNEUROSCI.
2177-05.2005
Caby, M. P., Lankar, D., Vincendeau-Scherrer, C., Raposo, G., and Bonnerot, C.
(2005). Exosomal-like vesicles are present in human blood plasma. Int.
Immunol. 17, 879–887. doi: 10.1093/intimm/dxh267
Chernyshev, V. S., Rachamadugu, R., Tseng, Y. H., Belnap, D. M., Jia, Y.,
Branch, K. J., et al. (2015). Size and shape characterization of hydrated
and desiccated exosomes. Anal. Bioanal. Chem. 407, 3285–3301.
doi: 10.1007/s00216-015-8535-3
Coleman, B. M., and Hill, A. F. (2015). Extracellular vesicles—their role in the
packaging and spread of misfolded proteins associated with neurodegenerative
diseases. Semin. Cell Dev. Biol. 40, 89–96. doi: 10.1016/j.semcdb.2015.
02.007
Dinkins, M. B., Dasgupta, S., Wang, G., Zhu, G., and Bieberich, E. (2014).
Exosome reduction in vivo is associated with lower amyloid plaque load in the
5XFAD mouse model of Alzheimer’s disease. Neurobiol. Aging 35, 1792–1800.
doi: 10.1016/j.neurobiolaging.2014.02.012
Dinkins, M. B., Dasgupta, S., Wang, G., Zhu, G., He, Q., Kong, J. N., et al. (2015).
The 5XFAD mouse model of Alzheimer’s disease exhibits an age-dependent
increase in anti-ceramide IgG and exogenous administration of ceramide
further increases anti-ceramide titers and amyloid plaque burden. J. Alzheimers
Dis. 46, 55–61. doi: 10.3233/JAD-150088
Dinkins, M. B., Enasko, J., Hernandez, C., Wang, G., Kong, J., Helwa, I.,
et al. (2016). Neutral sphingomyelinase-2 deficiency ameliorates
Alzheimer’s disease pathology and improves cognition in the 5XFAD
mouse. J. Neurosci. 36, 8653–8667. doi: 10.1523/JNEUROSCI.1429-
16.2016
Eisele, Y. S., Bolmont, T., Heikenwalder, M., Langer, F., Jacobson, L. H.,
Yan, Z. X., et al. (2009). Induction of cerebral β-amyloidosis: intracerebral
versus systemic Aβ inoculation. Proc. Natl. Acad. Sci. U S A 106, 12926–12931.
doi: 10.1073/pnas.0903200106
Eisele, Y. S., Obermüller, U., Heilbronner, G., Baumann, F., Kaeser, S. A.,
Wolburg, H., et al. (2010). Peripherally applied Aβ-containing inoculates
Frontiers in Aging Neuroscience | www.frontiersin.org 10 February 2017 | Volume 9 | Article 12
Zheng et al. Exosomes in Alzheimer’s Disease Pathology
induce cerebral β-amyloidosis. Science 330, 980–982. doi: 10.1126/science.
1194516
Fevrier, B., Vilette, D., Archer, F., Loew, D., Faigle, W., Vidal, M., et al. (2004).
Cells release prions in association with exosomes. Proc. Natl. Acad. Sci. U S A
101, 9683–9688. doi: 10.1073/pnas.0308413101
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E.,
Schwartz, J. B., et al. (2015). Identification of preclinical Alzheimer’s disease
by a profile of pathogenic proteins in neurally derived blood exosomes: a
case-control study. Alzheimers Dement. 11, 600.e1–607.e1. doi: 10.1016/j.jalz.
2014.06.008
Fitzner, D., Schnaars, M., van Rossum, D., Krishnamoorthy, G., Dibaj, P.,
Bakhti, M., et al. (2011). Selective transfer of exosomes from oligodendrocytes
to microglia by macropinocytosis. J. Cell Sci. 124, 447–458. doi: 10.1242/jcs.
074088
Flanary, B. (2005). The role of microglial cellular senescence in the aging
and Alzheimer diseased brain. Rejuvenation Res. 8, 82–85. doi: 10.1089/rej.
2005.8.82
Frautschy, S. A., Yang, F., Irrizarry, M., Hyman, B., Saido, T. C., Hsiao, K., et al.
(1998). Microglial response to amyloid plaques in APPsw transgenic mice. Am.
J. Pathol. 152, 307–317.
Frost, B., and Diamond,M. I. (2010). Prion-like mechanisms in neurodegenerative
diseases. Nat. Rev. Neurosci. 11, 155–159. doi: 10.1038/nrn2786
Goetzl, E. J., Boxer, A., Schwartz, J. B., Abner, E. L., Petersen, R. C., Miller, B. L.,
et al. (2015). Altered lysosomal proteins in neural-derived plasma exosomes
in preclinical Alzheimer disease. Neurology 85, 40–47. doi: 10.1212/WNL.
0000000000001702
Guo, B. B., Bellingham, S. A., and Hill, A. F. (2016). Stimulating the release
of exosomes increases the intercellular transfer of prions. J. Biol. Chem. 291,
5128–5137. doi: 10.1074/jbc.m115.684258
György, B., Pálóczi, K., Kovács, A., Barabás, E., Bek ´´o, G., Várnai, K., et al. (2014).
Improved circulating microparticle analysis in acid-citrate dextrose (ACD)
anticoagulant tube. Thromb. Res. 133, 285–292. doi: 10.1016/j.thromres.2013.
11.010
Hamaguchi, T., Eisele, Y. S., Varvel, N. H., Lamb, B. T., Walker, L. C., and
Jucker, M. (2012). The presence of Aβ seeds and not age per se, is critical to
the initiation of Aβ deposition in the brain. Acta Neuropathol. 123, 31–37.
doi: 10.1007/s00401-011-0912-1
Haney, M. J., Klyachko, N. L., Zhao, Y., Gupta, R., Plotnikova, E. G., He, Z., et al.
(2015). Exosomes as drug delivery vehicles for Parkinson’s disease therapy.
J. Control. Release 207, 18–30. doi: 10.1016/j.jconrel.2015.03.033
Harris, J. A., Devidze, N., Verret, L., Ho, K., Halabisky, B., Thwin, M. T.,
et al. (2010). Transsynaptic progression of amyloid-β-induced neuronal
dysfunction within the entorhinal-hippocampal network. Neuron 68, 428–441.
doi: 10.1016/j.neuron.2010.10.020
Heilbronner, G., Eisele, Y. S., Langer, F., Kaeser, S. A., Novotny, R.,
Nagarathinam, A., et al. (2013). Seeded strain-like transmission of
β-amyloid morphotypes in APP transgenic mice. EMBO Rep. 14, 1017–1022.
doi: 10.1038/embor.2013.137
Hickman, S. E., Allison, E. K., and El Khoury, J. (2008). Microglial
dysfunction and defective β-amyloid clearance pathways in aging Alzheimer’s
disease mice. J. Neurosci. 28, 8354–8360. doi: 10.1523/JNEUROSCI.0616-
08.2008
Jaunmuktane, Z., Mead, S., Ellis, M., Wadsworth, J. D. F., Nicoll, A. J., Kenny, J.,
et al. (2015). Evidence for human transmission of amyloid-β pathology
and cerebral amyloid angiopathy. Nature 525, 247–250. doi: 10.1038/nature
15369
Kandimalla, R., Manczak, M., Fry, D., Suneetha, Y., Sesaki, H., and Reddy, P. H.
(2016a). Reduced dynamin-related protein 1 protects against phosphorylated
tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s
disease. Hum. Mol. Genet. doi: 10.1093/hmg/ddw312 [Epub ahead of
print].
Kandimalla, R., Vallamkondu, J., Corgiat, E. B., and Gill, K. D.
(2016b). Understanding aspects of aluminum exposure in Alzheimer’s
disease development. Brain Pathol. 26, 139–154. doi: 10.1111/bpa.
12333
Kokubo, H., Saido, T. C., Iwata, N., Helms, J. B., Shinohara, R., and Yamaguchi, H.
(2005). Part of membrane-bound Aβ exists in rafts within senile plaques
in Tg2576 mouse brain. Neurobiol. Aging 26, 409–418. doi: 10.1016/j.
neurobiolaging.2004.04.008
Korotzer, A. R., Pike, C. J., and Cotman, C. W. (1993). β-Amyloid peptides
induce degeneration of cultured rat microglia. Brain Res. 624, 121–125.
doi: 10.1016/0006-8993(93)90068-x
Lacroix, R., Judicone, C., Mooberry, M., Boucekine, M., Key, N. S., Dignat-
George, F., et al. (2013). Standardization of pre-analytical variables in
plasma microparticle determination: results of the International Society
on Thrombosis and Haemostasis SSC Collaborative workshop. J. Thromb.
Haemost. doi: 10.1111/jth.12207 [Epub ahead of print].
Luo, X. G., Ding, J. Q., and Chen, S. D. (2010). Microglia in the aging brain:
relevance to neurodegeneration. Mol. Neurodegener. 5:12. doi: 10.1186/1750-
1326-5-12
Manczak, M., Kandimalla, R., Fry, D., Sesaki, H., and Reddy, P. H. (2016).
Protective effects of reduced dynamin-related protein 1 against amyloid
β-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s
disease. Hum. Mol. Genet. doi: 10.1093/hmg/ddw330 [Epub ahead of print].
Marciniuk, K., Taschuk, R., and Napper, S. (2013). Evidence for prion-like
mechanisms in several neurodegenerative diseases: potential implications
for immunotherapy. Clin. Dev. Immunol. 2013:473706. doi: 10.1155/2013/
473706
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C.,
Kilger, E., et al. (2006). Exogenous induction of cerebral β-amyloidogenesis
is governed by agent and host. Science 313, 1781–1784. doi: 10.1126/science.
1131864
Momen-Heravi, F., Balaj, L., Alian, S., Trachtenberg, A. J., Hochberg, F. H.,
Skog, J., et al. (2012). Impact of biofluid viscosity on size and sedimentation
efficiency of the isolatedmicrovesicles. Front. Physiol. 3:162. doi: 10.3389/fphys.
2012.00162
Osteikoetxea, X., Balogh, A., Szabó-Taylor, K., Németh, A., Szabó, T. G.,
Pálóczi, K., et al. (2015). Improved characterization of EV preparations
based on protein to lipid ratio and lipid properties. PLoS One 10:e0121184.
doi: 10.1371/journal.pone.0121184
Pardridge, W. M. (2012). Drug transport across the blood-brain barrier.
J. Cereb. Blood Flow Metab. 32, 1959–1972. doi: 10.1038/jcbfm.
2012.126
Perez-Gonzalez, R., Gauthier, S. A., Kumar, A., and Levy, E. (2012). The exosome
secretory pathway transports amyloid precursor protein carboxyl-terminal
fragments from the cell into the brain extracellular space. J. Biol. Chem. 287,
43108–43115. doi: 10.1074/jbc.M112.404467
Pisitkun, T., Shen, R. F., and Knepper, M. A. (2004). Identification and proteomic
profiling of exosomes in human urine. Proc. Natl. Acad. Sci. U S A 101,
13368–13373. doi: 10.1073/pnas.0403453101
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., et al.
(2006). Alzheimer’s disease β-amyloid peptides are released in association with
exosomes. Proc. Natl. Acad. Sci. U S A 103, 11172–11177. doi: 10.1073/pnas.
0603838103
Rogers, J., Luber-Narod, J., Styren, S. D., and Civin, W. H. (1988). Expression
of immune system-associated antigens by cells of the human central nervous
system: relationship to the pathology of Alzheimer’s disease. Neurobiol. Aging
9, 339–349. doi: 10.1016/s0197-4580(88)80079-4
Scott, D. J., Harding, S. E., and Rowe, A. J. (2005). Analytical
Ultracentrifugation: Techniques and Methods. London: Royal Society of
Chemistry.
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., et al.
(2014). Plasma exosomal α-synuclein is likely CNS-derived and increased in
Parkinson’s disease. Acta Neuropathol. 128, 639–650. doi: 10.1007/s00401-014-
1314-y
Stalder, M., Phinney, A., Probst, A., Sommer, B., Staufenbiel, M., and
Jucker, M. (1999). Association of microglia with amyloid plaques in brains
of APP23 transgenic mice. Am. J. Pathol. 154, 1673–1684. doi: 10.1016/s0002-
9440(10)65423-5
Styren, S. D., Civin, W. H., and Rogers, J. (1990). Molecular, cellular and
pathologic characterization of HLA-DR immunoreactivity in normal elderly
and Alzheimer’s disease brain. Exp. Neurol. 110, 93–104. doi: 10.1016/0014-
4886(90)90054-v
Tamboli, I. Y., Barth, E., Christian, L., Siepmann, M., Kumar, S., Singh, S., et al.
(2010). Statins promote the degradation of extracellular amyloid β-peptide
by microglia via stimulation of exosome-associated insulin-degrading enzyme
(IDE) secretion. J. Biol. Chem. 285, 37405–37414. doi: 10.1074/jbc.M110.
149468
Frontiers in Aging Neuroscience | www.frontiersin.org 11 February 2017 | Volume 9 | Article 12
Zheng et al. Exosomes in Alzheimer’s Disease Pathology
Vella, L. J., Greenwood, D. L., Cappai, R., Scheerlinck, J. P., and Hill, A. F. (2008).
Enrichment of prion protein in exosomes derived from ovine cerebral spinal
fluid.Vet. Immunol. Immunopathol. 124, 385–393. doi: 10.1016/j.vetimm.2008.
04.002
Vella, L. J., Sharples, R. A., Lawson, V. A., Masters, C. L., Cappai, R., and
Hill, A. F. (2007). Packaging of prions into exosomes is associated with
a novel pathway of PrP processing. J. Pathol. 211, 582–590. doi: 10.1002/
path.2145
Vingtdeux, V., Hamdane, M., Loyens, A., Gelé, P., Drobeck, H., Bégard, S., et al.
(2007). Alkalizing drugs induce accumulation of amyloid precursor protein
by-products in luminal vesicles of multivesicular bodies. J. Biol. Chem. 282,
18197–18205. doi: 10.1074/jbc.M609475200
Vingtdeux, V., Sergeant, N., and Buée, L. (2012). Potential contribution of
exosomes to the prion-like propagation of lesions in Alzheimer’s disease. Front.
Physiol. 3:229. doi: 10.3389/fphys.2012.00229
Yuyama, K., Sun, H., Mitsutake, S., and Igarashi, Y. (2012). Sphingolipid-
modulated exosome secretion promotes clearance of amyloid-β by
microglia. J. Biol. Chem. 287, 10977–10989. doi: 10.1074/jbc.M111.
324616
Yuyama, K., Sun, H., Sakai, S., Mitsutake, S., Okada, M., Tahara, H.,
et al. (2014). Decreased amyloid-β pathologies by intracerebral loading of
glycosphingolipid-enriched exosomes in Alzheimer model mice. J. Biol. Chem.
289, 24488–24498. doi: 10.1074/jbc.M114.577213
Yuyama, K., Sun, H., Usuki, S., Sakai, S., Hanamatsu, H., Mioka, T., et al.
(2015). A potential function for neuronal exosomes: sequestering intracerebral
amyloid-β peptide. FEBS Lett. 589, 84–88. doi: 10.1016/j.febslet.2014.
11.027
Zheng, T., Lv, Q., Lei, X., Yin, X., and Zhang, B. (2015). Spatial distribution of
5-hydroxymethyl cytosine in rat brain and temporal distribution in striatum.
Neurochem. Res. 40, 688–697. doi: 10.1007/s11064-015-1515-3
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Zheng, Pu, Chen, Mao, Guo, Pan, Zhang, Zhang, Sun and Zhang.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution and reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Aging Neuroscience | www.frontiersin.org 12 February 2017 | Volume 9 | Article 12
